With increasing numbers of technical developments and clinical studies, pioneering cellular/gene therapies are now available that could cure life-threatening disease. Cellular/gene therapy products are broad-ranging and complicated, and thereby bring challenges for clinical review by regulatory agencies. This review discusses principles for the clinical review of cellular therapy products, including protection of clinical trial populations, pharmacodynamics, pharmacokinetics, dose evaluation, clinical efficacy, clinical safety, and risk-management plans. Based on these principles, key points in the clinical review of chimeric antigen receptor T-cell therapy are also discussed.
Get full access to this article
View all access options for this article.
References
1.
HillJA, LiD, HayKA, et al.Infectious complications of CD19-targeted chimeric antigen receptor-modified T cell immunotherapy. Blood, 2018; 131:121–130.
2.
LockeFL, NeelapuSS, BartlettNL, et al.Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther, 2017; 25:285–295.
3.
BaikCS, RubinEH, FordePM, et al.Immuno-oncology clinical trial design: limitations, challenges, and opportunities. Clin Cancer Res, 2017; 23:4992–5002.
4.
LeeDW, KochenderferJN, Stetler-StevensonM, et al.T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a Phase 1 dose-escalation trial. Lancet, 2015; 385:517–528.
5.
TurtleCJ, HayKA, HanafiLA, et al.Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-Specific chimeric antigen receptor-modified T cells after failure of ibrutinib. J Clin Oncol, 2017; 35:3010–3020.
6.
LimWA, JuneCH. The principles of engineering immune cells to treat cancer. Cell, 2017; 168:724–740.
7.
TurtleCJ, HanafiL-A, BergerC, et al.Immunotherapy of non-Hodgkins lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med, 2016; 8:355ra116–355ra116.
8.
LeeDW, GardnerR, PorterDL, et al.Current concepts in the diagnosis and management of cytokine release syndrome. Blood, 2014; 124:188–195.
9.
TurtleCJ, HanafiL, BergerC, et al.CD19 CAR-T cells of defined CD4 + : CD8 + composition in adult B cell ALL patients. J Clin Invest, 2016; 1:1–16.
10.
NeelapuSS, TummalaS, KebriaeiP, et al.Chimeric antigen receptor T-cell therapy—assessment and management of toxicities. Nat Rev Clin Oncol, 2018; 15:47–62.
11.
HowardSC, JonesDP, PuiC-H. The tumor lysis syndrome. N Engl J Med, 2011; 364:1844–1854.
12.
SinghN, PerazzelliJ, GruppSA, et al.Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. Sci Transl Med, 2016; 8:320ra3.
